Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | CFTR | P13569 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2391700 | 1.00 | GAA (0.43) | GAAALDH1A1CFTRMAPTCYP1A2 | |
| SCHEMBL2389464 | 0.81 | CFTR (0.43) | ALDH1A1CFTRMAPTCYP1A2CYP2C19 | |
| SCHEMBL2390059 | 0.77 | CYP1A2 (0.40) | GAAALDH1A1CFTRMAPTCYP1A2 | |
| SCHEMBL2388746 | 0.75 | CFTR (0.41) | GAAALDH1A1CFTRMAPTCYP1A2 | |
| SCHEMBL2388410 | 0.75 | CFTR (0.63) | GAAALDH1A1CFTRMAPTCYP1A2 | |
| SCHEMBL5165192 | 0.75 | CFTR (0.52) | GAAALDH1A1CFTRMAPTCYP1A2 | |
| SCHEMBL2390746 | 0.75 | CYP1A2 (0.39) | GAAALDH1A1CFTRCYP1A2CYP2C19 | |
| SCHEMBL2388317 | 0.74 | CFTR (0.40) | ALDH1A1CFTRMAPTCYP1A2CYP2C19 | |
| SCHEMBL2387665 | 0.73 | SMN1; SMN2 (0.44) | GAAALDH1A1CFTRMAPTCYP1A2 | |
| SCHEMBL30140022 | 0.72 | ALDH1A1 (0.48) | GAAALDH1A1CFTRMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130296332-A1 | 1H-QUINAZOLINE-2,4-DIONES | NOVARTIS AG (CH) | 2013-11-07 | — | — | US | disclosed |
| US-8513268-B2 | 1H-quinazoline-2,4-diones processes for their production, pharmaceutical compositions, and treatment for epilepsy | NOVARTIS AG (CH) | 2013-08-20 | — | — | US | disclosed |
| EP-2476671-A1 | 1H-Quinazoline-2,4-diones | Novartis AG (CH) | 2012-07-18 | — | — | EP | disclosed |
| EP-2468732-A1 | 1H-Quinazoline-2,4-diones | Novartis AG (CH) | 2012-06-27 | — | — | EP | disclosed |
| EP-2463278-A1 | 1H-QUINAZ0LINE-2,4-DIONES AND THEIR USE AS AMPA-RECEPTOR LIGANDS | Novartis AG (CH) | 2012-06-13 | — | — | EP | disclosed |
| US-20110294818-A1 | 1H-QUINAZOLINE-2,4-DIONES | NOVARTIS AG | 2011-12-01 | — | — | US | disclosed |
| US-8012988-B2 | N-(2,4-dioxo-6-(tetrahydrofuran-2-yl)-7-(trifluoromethyl)-1,4-dihydro-2H-quinazolin-3-yl)methanesulfonamide | NOVARTIS AG (CH) | 2011-09-06 | — | — | US | disclosed |
| US-20100144747-A1 | 1H-QUINAZ0LINE-2,4-DIONES | NOVARTIS AG | 2010-06-10 | — | — | US | disclosed |
| US-7655666-B2 | Substituted 1H-quinazoline-2,4-diones useful as AMPA receptor ligands | NOVARTIS AG (CH) | 2010-02-02 | — | — | US | disclosed |
| US-20080153836-A1 | N-(2,4-Dioxo-1,4-dihydro-2H-quinazolin-3-yl)-methanesulfonamide derivatives; condensation, cyclization, reduction; AMPA (A-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor antagonists; schizophrenia, bipolar disorders, Parkinson's Disease, antiepileptic agents; psychological disorders | NOVARTIS AG (CH) | 2008-06-26 | — | — | US | disclosed |
| EP-1871749-A1 | 1H-QUINAZ0LINE-2,4-DIONES AND THEIR USE AS AMPA-RECEPTOR LIGANDS | Novartis AG (US) | 2008-01-02 | — | — | EP | disclosed |
| WO-2006108591-A1 | 1H-QUINAZ0LINE-2,4-DIONES AND THEIR USE AS AMPA-RECEPTOR LIGANDS | NOVARTIS AG (CH) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294818-A1 | 1H-QUINAZOLINE-2,4-DIONES | CYP1A2, QDPR, CYP3A7 | GAA 1401/4885ALDH1A1 115/4885CFTR 1584/4885 |
| US-20100144747-A1 | 1H-QUINAZ0LINE-2,4-DIONES | CYP3A7, CYP1A2, UGT1A7 | GAA 1484/4885ALDH1A1 143/4885CFTR 1356/4885 |
| US-20080153836-A1 | N-(2,4-Dioxo-1,4-dihydro-2H-quinazolin-3-yl)-methanesulfonamide derivatives; condensation, cyclization, reduction; AMPA (A-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor antagonists; schizophrenia, bipolar disorders, Parkinson's Disease, antiepileptic agents; psychological disorders | GRIN2A, GRIN1, GRIN2D | GAA 1433/4885ALDH1A1 804/4885CFTR 1840/4885 |
| US-20130296332-A1 | 1H-QUINAZOLINE-2,4-DIONES | CYP1A2, QDPR, CYP3A7 | GAA 1401/4885ALDH1A1 115/4885CFTR 1584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.